Skip Navigation
Search
Back to Search Innovations
Triazamacrocycle-derived chelators for the coordination of imaging and therapy metal ions
Rapid and inert radiolabeling  with an array of radioactive isotopes suitable for medical imaging and therapy approaches.

Background

Personalized medicine, or individually tailored patient treatment, is an emerging clinical management paradigm. In nuclear medicine, this entails exploiting diagnostic techniques, such as non-invasive imaging by means of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), to modify radiotherapeutic treatment regimes. If the same drug is labeled with a diagnostic and a therapeutic radionuclide for sequential imaging and treatment, the approach is considered “theranostic.” Theranostic isotope pairs enable diagnostic imaging that is directly, accurately and reliably predictive of therapy and imaging can be carried out for prolonged periods of time. However, in order to utilize metallic theranostic isotope pairs, customized chelation approaches are required that enable targeted delivery of isotope payload to the site of interest.

Technology

44Scandium and 64copper have recently emerged as an attractive, short-lived, PET isotopes with a matched radiotherapeutic isotope for radio therapy (47Sc, 67Cu, 177Lu). In this invention, novel, modular chemical entities with high affinity to copper, scandium and lutetium radioisotopes and a freely functionalizable moiety have been synthesized. These constructs are suitable to kit-type formulations for single-step radiochemical synthesis of diagnostic and therapeutic entities radiolabeled with scandium, copper and lutetium isotopes, and are readily suitable for applications using other any desirable targeting vectors of peptidic/small molecule, protein or antibody nature.

Advantages

This technology allows for rapid and inert radiolabeling  with an array of radioactive isotopes suitable for imaging and therapy approaches. This renders the technology superior to currently commercially available 18F-, 68G-, and 177Lu-based tracers.

Application

Cancer diagnostics and therapeutics.

Inventors

Eszter Boros, Assistant Professor, Chemistry
Brett Vaughn, , Chemistry

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for licensing

Licensing Contact

Valery Matthys, Licensing Associate, Technology Licensing, valery.matthys@stonybrook.edu,

Patent Status

  PCT/US2019/038318

Preclinical, animal data available.

Novel Process for Measuring Nitrate/Nitrite and Ammonium in Wastewater Simultaneously
Using a strong alkaline solution and a gas-permeable membrane to measure the concentration of ammonium/ammonia/nitrite/nitrate in wastewater

 

Source: Hermann Hammer, https://pixabay.com/photos/sewage-plant-wastewater-2224933/, Pixabay License

Background

Due to the growing problems with the conventional processes for treating wastewater, there has recently been a spur in the development and design of a low‑cost nitrogen sensor package that can measure and monitor nitrate and ammonium in septic systems. Conventional processes for wastewater treatments are either too expensive, too ineffective, or simply too time-consuming. Therefore, there is a need for a method and apparatus that is cost‑effective and can improve the treatment of wastewater streams.    

Technology

This method involves using very small quantities of inexpensive and innocuous chemical reagents to selectively separate and detect nitrate/nitrite and ammonium from wastewater in a compact sensor unit. The sensor shows a good liner response for both nitrate/nitrite and ammonium/ammonia in the range of 0 to 70 N-mg/L nitrogen (a range deemed indicative of market requirements) with a detection limit of 1 N-mg/L. It can be remotely operated to measure hourly, daily, or any scheduled time with high accuracy (bias < ±20%) and precision (RSD < 10%). The sensor is designed for in-situ, long-term deployment in wastewater systems with low maintenance (i.e. no more than quarterly) and remote data transmission. It has passed the performance criteria set by the USEPA and won Phase II of the “Advanced Septic System Nitrogen Sensor Challenge” sponsored by the US EPA in partnership with The Nature Conservancy (TNC), the U.S. Geological Survey (USGS) and others, and the technical performance has been thoroughly vetted by the EPA, Battelle and Massachusetts Alternatives Septic System Testing Center (MASSTC). The sensor is now undergoing the six-month verification of the technology’s performance by the globally-recognized International Organization for Standardization (ISO) Environmental Technology Verification 14034 standard (ISO 14034).

Advantages

Low-cost. High accuracy and precision. High selectivity for nitrate/nitrite and ammonium. There is no interference from color, turbidity, and hydrate cations and anions. Wide response range. Fast and real-time measurement. Continuous and automatic measurement. Long-term continuous deployment and long lifetime. High stability and low maintenance. Simultaneous measurement of nitrate/nitrite and ammonium in a single sensor package.

Application

Can be used to measure nitrate/nitrite and ammonium/ammonia in wastewater, water treatment plants, advanced septic systems, and in surface water and ground water with minor modification.

Inventors

Qingzhi Zhu, Associate Professor, School of Marine and Atmospheric Sciences

Licensing Potential

Development partner Commercial partner Licensing  

Licensing Status

Available for licensing.

Licensing Contact

James Martino, Licensing Specialist, OTLIR, james.martino@stonybrook.edu,

Patent Status

Provisional patent

62/983,911

Large-Scale Sentiment Analysis for News and Blogs
Please note, header image is purely illustrative. Source: Siobhán Grayson, Wikimedia Commons, CC BY-SA 4.0.

Background

Sentiment analysis of natural language texts is a large and growing field. Some methods for generating sentiment lexicons assume positive and negative sentiment using synonyms and antonyms. Such methods may not accurately capture the sentiment of a word. Other methods use semantics, such as "and" and "but", or tone/orientation to determine a sentiment of a word, but such methods may have low accuracy. Current methods for analyzing sentiment treat only single complete documents, for example, to determine if a movie review is good or bad or quantify opinion from a product review. Therefore, there is a need for a method of generating a more accurate sentiment lexicon and for determining a sentiment over a plurality of texts.

Technology

This technology uses statistical analysis of text streams to simultaneously monitor changes in reputation to thousands of distinct news entries. Commercial applications of this technology include 1) market research - the technology can analyze the reputation of people, products, and companies without the need for expensive surveys or polling, 2) financial analysis - the conversion of news data to time-series facilitates automated investment analysis, e.g. strengthening pair trading investment strategies by identifying companies without the need for expensive surveys/polling, 2) internet search engines - augmenting results by providing sentiment data on articles.

Advantages

Gives the ability to monitor entity sentiment as a time-series in any text stream, such as news or blogs, even if written in different languages and from different news sources.

Application

Commercial applications include: - Market Research- This technology can analyze the reputation of people, products, and companies without the need for expensive surveys or polling - Financial Analysis- The conversion of news data to time-series facilitates automated investment analysis - Internet Search Engines- augmenting results by providing sentiment data on articles

Inventors

Steven Skiena, Distinguished Teaching Professor, Computer Science
Namrata Godbole, Graduate Student, Computer Science
Manjunath Srinivasaiah, Graduate Student, Computer Science

Licensing Potential

Licensing

Licensing Status

Available for License.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patented

7,996,210 8,515,739

PI 3-Kinase Cancer Immunotherapy
Pancreatic cancer patients will be treated with a PI3K inhibitor to induce the cancer cells to reveal their antigens to the immune system
Source: Ravikanth Maddipati, https://visualsonline.cancer.gov/details.cfm?imageid=10654, public domain

Background

Standard chemotherapies have little impact on pancreatic cancer (PDAC) patient survival, and new T-cell therapies have yet to be successful in treating solid tumors. Phosphoinositide 3-kinase (PI3K), a critical downstream effector of Kras is strongly implicated in PDACs. Genetic ablation of PI3K in the pancreas completely protects mice against oncogenic Kras induced tumor formation. Yet, inhibitors that target PI3K do not induce dramatic regression of solid tumors when used as single agents in clinical trials. Stony Brook University researchers have identified one reason for this dichotomy that sheds light on new therapeutic strategies for treating solid tumors.

Technology

PI3K signaling mediates pancreatic tumor evasion from the immune system. The researchers at Stony Brook University have applied this finding to develop an immune therapy for pancreatic cancer. The therapy combines the use of small molecule PI3K inhibitors with genetically modified T-cells resistant to PI3K inhibitors to enable them to function properly in the presence of PI3K inhibitors. Pancreatic cancer patients will be treated with a PI3K inhibitor to induce the cancer cells to reveal their antigens to the immune system. These inhibitors in combination with the patients? own T cells, which are genetically modified to express inhibitor-resistant PI3K mutants, will enable these T cells to kill the pancreatic cancer cells.

Advantages

Potential for other solid tumors - Can be combined with CAR-T Therapy

Application

Pancreatic cancer or other solid tumors

Inventors

Richard Lin, Professor, Physiology & Biophysics

Licensing Potential

Licensing 

Licensing Status

Available for licensing.

Licensing Contact

Valery Matthys, Licensing Associate, Technology Licensing, valery.matthys@stonybrook.edu,

Patent Status

Provisional patent - Patent application submitted

Preclinical. Provisional filed

Method and Apparatus for High Efficiency X-ray Imager
An x-ray detector with improved dynamic range and sensitivity that improves the quantum efficiency of x-ray imagers
Source: Jonathan Borba, unsplash.com/photos/v_2FRXEba94, Unsplash Licence

Background

X-ray imaging experienced a ?digital revolution? in the early 2000s, with digital radiography systems being implemented with active matric flat panel images. Due to the compact size, rapid image readout and excellent image quality, AMFPI is being used not only for traditional x-ray imaging modalities such as general radiography and fluoroscopy, but also in tomographic imaging applications.

Technology

The detectors proposed here provide an improved dynamic range and sensitivity which is required in digital radiography. Improving optical photon conversion efficiency provides practical advantages for both avalanche and non-avalanche embodiments of the scintillator.

Advantages

This technology improves the quantum efficiency of indirect and hybrid x-ray imagers where optical photons need to be converted to electronic charge. The improvement in quantum efficiency can be orders of magnitude for green and red wavelengths.

Application

Radiology - Nanotechnology - Sensors

Inventors

Wei Zhao, Professor, Radiology
Amirhossein Goldan, Assistant Professor, Radiology
Adrian Howansky, Graduate Student, Radiology
Rick Lubinsky, Research Scientist, Department of Radiology
James Scheurmann, Ph.D Candidate, Department of Radiology
Jann Stavro, Ph.D Candidate, Department of Radiology

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Exclusive License - All Fields

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted

US Provisional Filed

Process for Predicting Community Real Estate Outcomes Using Social Media
Tracking information about communities that is not available otherwise to better predict prices
Source: paulbr75, pixabay.com/photos/home-for-sale-buy-sell-mortgage-1682316/, Pixabay Licence

Technology

This technology tracks information about communities that is not available otherwise. It has shown it can predict prices better than those variables alone.

Advantages

Inpart-Benefits

Inventors

Hansen Schwartz, Assistant Professor, Computer Science
Mohammadzaman Zamani, PhD Student, Computer Science

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook University seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Working prototype available for demonstration.

System and Methods for Virtual Pancreatoscopy
A virtual super-resolution pancreatoscopy method that can visualize the fine-scale structures.
Source: magicmine, stock.adobe.com/uk/181431302, stock.adobe.com

Background

Virtual endoscopy has been observed and claimed in many previous patents for several different organs. Among these organs is the colon, and the radiological imaging of virtual pancreatoscopy.

Technology

Pancreatoscopy is the endoscopic examination of the pancreatic ducts. In previous approaches, many patent methods showcase the general direction and colon fly through. The proposed technology is the ability to analyze fine-scale structures. The super-resolution technique extends imaging resolution. Rendering enables the interior surfaces within the pancreatic duct, allowing for viewing of geometrical structures of the duct.

Advantages

Proposed is a super-resolution technique which is the enabling factor for imaging resolution far beyond that of the clinical scanner. Enabled is the ability to extract fine-scale pancreatic duct geometry and inspect internal structures.

Application

Biomedical Informatics

Inventors

Yi Gao, Assistant Professor, Biomedical Informatics
Aaron Sasson, Professor, Surgery

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Stony Brook University seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Working prototype available for demonstration.

A Piezoelectric-triboelectric Heel Charger for Power-on-the-go
A heel charger that uses a level mechanism and a mechanical SSHI boosting circuit to provide electrical energy
Please note, header image is purely illustrative. Source: Frank Busch, unsplash.com/photos/9UUdERAEghM, Unsplash Licence

Background

Running out of battery power often results in life-threatening situations, whereas backup batteries are large, heavy and hazardous. In efforts to treat this unreliable aspect, proposed is an energy harvester. This is a clean alternative solution to such problems, with the ability to power electronics on the go.

Technology

This invention entails a high power density heel charger, providing a USB port or datable rechargeable battery. The high-power density charger consists of a mechanical part and an electrical part. Current implementations consist of a heel charger that turns the shoe into a charging station. This uses a levered piezoelectric-triboelectric multimodal mechanism, a mechanical synchronized switch and a harvesting inductor conditioning circuit. The shoe has barely noticeable weight, expecting to provide electrical energy equivalent to 6 minutes of continuous phone call with just 1 hour of walking.

Advantages

Amplifying the displacement of footsteps by the lever mechanism to achieve higher efficiency.

Application

The ability to target large markets such as mobile energy harvesting, remote sensing, hikers and marine corps, etc.

Inventors

Ya Wang, Assistant Professor, Mechanical Engineering
Haili Liu, Postdoctoral Associate, Mechanical Engineering

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent Application Published: US-2020-0177105-A1

Working prototype available for demonstration.

Development of a Pediatric Tuberculosis Diagnostic Test
A lipoprotein diagnostic marker for TB disease ideal for a simple diagnostic assay from a finger prick blood or serum
Source: andriano_cz, stock.adobe.com/uk/175903167, stock.adobe.com

Background

The inadequate sensitivity of available organism-based TB diagnostic tools in children, the wide spectrum of disease observed in children, and the non-specific signs and symptoms especially in young and HIV-children, contribute to diagnostic delay and missed opportunities to detect childhood TB.

Technology

Researchers at Stony Brook have identified changes in a serum lipoprotein that result from a combination of host and TB pathogen activity. The MTB-modified lipoprotein (TLP) is thereby a more specific diagnostic marker for TB disease than the conventional host markers. Development of antibodies against the TLP marker enables the production of a simple in-vitro diagnostic (IVD) assay for pediatric tuberculosis using as finger-prick blood or serum.

Advantages

Non-sputum based diagnostic ELISA test - Novel marker - Novel antibodies to TLP

Application

Diagnostic test for pediatric and adult TB.

Inventors

Nicole Sampson, Professor and Interim Dean, Chemistry
Xinxin Yang, Sr. Postdoctoral Researcher, Chemistry

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook is seeking a commercial partner for licensing and/or collaborative research.

Licensing Contact

Valery Matthys, Licensing Associate, Technology Licensing, valery.matthys@stonybrook.edu,

Patent Status

Patent application submitted

Data using serum from pediatric patients. PCT application filed

Hybrid Active Matrix Flat Panel Imager
A hybrid x-ray detector that absorbs incident rays directly and indirectly, and the photoconductor can sense both x-rays and optical photons
Source: Yurok Aleksandrovich, stock.adobe.com/uk/2003066, stock.adobe.com

Background

X-ray detectors currently commercially available consist of direct and indirect detectors. Direct detectors take x-ray inputs and are directly converted to electron hole pairs and digitized through the readout electronics. Common photoconductors are amorphous selenium. Indirect detectors use a phosphor screen to later convert x-rays to optical photons, absorbed in a photodiode and digitized. Higher energy applications and current photoconductors do not have sufficient quantum efficiency.

Technology

This invention is a new hybrid detector where incident x-rays are absorbed via both direct interactions in the photoconductor and indirect interaction in the scintillator. This method enables the photoconductor to sense both x-rays and optical photons. The hybrid structure results in spatial resolution and dose efficiency improvement beyond current direct and indirect detectors.

Advantages

The newly proposed model as compared to current direct and indirect detectors available has better spatial resolution, improved dose efficiency and higher absorption efficiency combined with high spatial resolution resulting in better detective quantum.

Application

Radiology

Inventors

Anthony Lubinsky, Research Assistant Professor, Radiology
Wei Zhao, Professor, Radiology
Adrian Howansky, Graduate Student, Radiology
James Scheuermann, Graduate Student, Radiology

Licensing Potential

Development partner - Commercial partner - Licensing 

Licensing Status

Available for License. Stony Brook University seeks to develop and commercialize by an exclusive or non-exclusive license agreement and/or sponsored research with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted Publication US-2019-0388042-A1

Cavity-enhanced Two-dimensional Spectrometer
Inpart-Short description
Source: Michael Maasen, https://unsplash.com/photos/rJE8oIF4uco, Unsplash License

Background

Fundamental studies in physics and chemistry include spectroscopy of gas-phase atoms and molecules, developing essential components of quantum mechanics.

Technology

This invention is a method to perform passively amplified 2D spectroscopy experiments, and a frequency comb and optical cavities approach was implemented. Implementation is created through coupling multiple frequency combs to higher-order cavity modes, background-free, cavity-enhanced 2D spectroscopy signals are naturally generated via phase cycling. Cavity-enhanced ultrafast transient absorption spectroscopy, the signal to noise is enhanced by a factor proportional to the cavity nesse squared.

Advantages

The sensitivity will be probably 3-4 orders of magnitude higher than conventional 2D spectrometers and it can use a lower peak power laser which is less expensive.

Application

Clinical - Optics and Photonics

Inventors

Thomas Allison, Assistant Professor,

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook University seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted - Provisional patent

US Provisional Filed

Method of Treating Alzheimer's Disease with X-ray Minibeams
An x-ray therapy method for treating Alzheimer's disease that maintains a tissue-sparing effect allowing for higher doses
Source: Natasha Connell, https://unsplash.com/photos/byp5TTxUbL0, Unsplash License

Background

Alzheimer?s Disease is the most common form of dementia among the elderly and affects over five million individuals in the United States. To date, there is no definitive treatment to cure or halt the progression of Alzheimer?s Disease. Approved pharmacotherapies offer only modest and transient symptomatic benefits.

Technology

The proposed x-ray method replaces conventional x-ray exposures used in previous studies. This alternative is an efficient therapeutic outcome, one that is maintaining a tissue-sparing effect.

Advantages

Treatment method is centered around maintaining a tissue-sparing effect allowing for 10X higher dose limits than conventional x-rays.

Application

Inpart-Applications

Inventors

Avraham Dilmanian, Research Professor, Department of Radiology
Renee Cattell, Student, Radiology
Lev Bangiyev, DO,

Licensing Potential

Development partner - Commercial partner - Licensing 

Licensing Status

Available for license.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Provisional patent - Patent application submitted

Pre-clinical. - Provisional Patent Filed

Similarity Preserving Color Mapping Scheme for Multivariate Data
A framework that uses the HSL color space for mapping data to color and is ideal for environmental assessments and scientific simulations
Source: fauxels, https://www.pexels.com/photo/photo-of-person-holding-mobile-phone-3183153/, Pexels License.

Background

Mapping data to color has a rich history and several well-tested color schemes have emerged. Most of these, however are defined for scalar data where the scalar value indexes a one-dimensional table that returns an RGB color triple. Schemes assign color to different, usually disjoint materials and then use standard blending functions to handle areas where materials overlap or mix together. This process forces graphical rendering of simulations.

Technology

Framework generalizes straightforward interpolation methods defined for the bivariate and trivariate using generalized barycentric interpolation. Instead of using an N-sided polygon, optimized is the placement of the vertices in terms of the pairwise correlation of the variables, such that factors with similar behavior map to similar primary color. The proposed technology will yield an automatic and data-driven method for visually encoding similarities of variables which is far more accurate. This framework makes use of the HSL color space, innovatively mapping it into the interior of the N-sided polygon. Color space is natural since color is often expressed as HSL triple.

Advantages

Using HSL space users will be able to see the distribution of the data in the context of the colors they are mapped into. Users can paint into the space, using objects selected in the native data space as a reference for the color to be painted

Application

Data occurs frequently in many applications- demographic assessment, environmental monitoring, scientific simulations.

Inventors

Klaus Mueller, Professor, Computer Science
Shenghui Cheng, Granduate Student, Computer Science

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook University seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted - Provisional patent

Working prototype available for demonstration. US Provisional Filed

Data Memes: Automatically Merging Data with Supporting Visuals
A framework for displaying user data as data memes, an artistic visualization of data for increasing engagement
Source: Lukas Blazek, unsplash.com/photos/mcSDtbWXUZU, Unsplash Licence

Background

The information age is upon us and in recent years millions of terabytes of data are generated every day. This growing chunk of data is related to personal lives- information about ourselves and communities and issues that have personal relevance. In efforts to make sense of it, they have turned information into visuals. These visuals are designed to represent opinions and alongside using charts.

Technology

This framework uses what is known about the data and automatically queries web-scale image search engines such as Google Image for a set of images matching the user?s choice. Data memes appeal to masses by embracing mainly basic charts, specifically pie, line and bar charts.

Advantages

General users are indeed more engaged with data when presented in a data meme, as opposed to a conventional chart. Data memes are artistic visuals of data in which data is merged with an image such that the structure of image will support meaning.

Inventors

Klaus Mueller, Professor, Computer Science
Darius Coelho, Student, Computer Science

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted - Provisional patent

Working prototype available for demonstration. - US Provisional Filed

Fused Computation of Convolutional Neural Network Layers
A CNN hardware accelerator that improves energy efficiency ideal for architectures that focus on the dataflow across convolutional layers
Source: Bartosz Kwitkowski, unsplash.com/photos/SJ5TmRRSM1U, Unsplash Licence.

Background

Deep convolutional neural networks (CNNs) are rapidly becoming the dominant approach to computer vision and a major component of many other pervasive machine learning tasks.

Technology

Developed is a novel CNN hardware accelerator with a new architecture and design methodology. Modified is the order in which the original input data are brought on to the chip. The design approach is a pyramid-shaped multi-layer sliding window, allowing effective on-chip caching during evaluation. Caching in turn reduces the off-chip memory bandwidth requirements.

Advantages

The proposed technology is an improvement in energy efficiency by minimizing data movements and improving performance.

Application

CNN accelerator architectures that focus on the dataflow across convolutional layers.

Inventors

Michael Ferdman, , Computer Science
Peter Milder, , Electrical Engineering
Monaj Alwani, student, Computer Science

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for License. Stony Brook University seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted - Provisional patent

US Provisional Filed

Smart Wristband For Tooth Brush Monitoring
A wristband that monitors hand gestures in real-time and assesses the quality of tooth brushing technique
Source: Superkitina, unsplash.com/photos/rCT928GIboM, Unsplash Licence

Background

Tooth decay and gum diseases are among the most prevalent chronic diseases in both children and adults, most of these issues stem from an accumulation of dental plague and failure in teeth care. Although regular tooth brushing is recommended by the American Dental Association, today?s electric toothbrushes don?t detect the quality of tooth brushing. This application utilizes a learning algorithm to detect tooth brushing activity. The system is able to collect data in regards to surface coverage and brushing frequency.

Technology

Using real-time feedback, the application is able to detect a variety of different gestures. The watch is connected to a hand held device using Blue tooth, sending results to be displayed and creating a brushing quality assessment. Incorrect tooth brushing technique is less effective and may lead to the permanent damage of the enamel.

Advantages

Extensive evaluation results demonstrate that the design reliably detects the brushing activity with 96.4% accuracy, and recognizes gestures of brushing different surfaces of teeth with 83.6% accuracy.

Inventors

Shan Lin, Assistant Professor, Electrical Engineering

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted - Provisional patent

US Provisional Filed

Condensing Flue Gas for Sub-Ambient Evaporative Cooling and Cool Storage
An evaporator and condenser arrangement that allows indefinite heat storage times for power plants without additional refrigeration systems
Source: Wim van 't Einde, unsplash.com/photos/nneWpcgo0DE, Unsplash Licence

Background

A thermosyphon uses the latent heat of vaporization rather than a temperature gradient for heat transfer. Power plants don?t require a large body of water for cooling and consume little to no water for operation, significantly enhancing US electricity potential. Thermal resistance for heat transfer can be reduced, the condensate will be stored and used for subsequent evaporative cooling using commercially available technologies.

Technology

The evaporator and condenser are arranged so that the vapor and liquid flows are co-current. The device performance is enhanced by removing the flooding limit while having a thinner evaporating film. Working fluid delivered to the top of the evaporator is actively metered by a pump and control system to ensure that only a liquid film exists on the walls. Traditional liquid pool and limiting issues are no longer involved. Cooling is stored as liquid water, rather than a thermal mass held at a cooler temperature than the ambient, causing the storage time to be indefinite and heat leakage no longer being an issue.

Advantages

The proposed technology will be developed in stand-alone modules that can be added or removed to increase or decrease capacity, if a single module fails the system will still operate.

Application

Using a thermosyphon to move heat from the flue gas to the ambient with no additional refrigeration system.

Inventors

Jon Longtin, Associate Professor, Mechanical Engineering

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook University seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted

US Provisional Filed

Novel Prodrugs for Selective Anticancer Therapy
Novel methods to make anticancer prodrugs by conjugating unique dual-substrate biochemical modules to known or novel chemotherapeutic drugs
Source: Science in HD, unsplash.com/photos/qmLwjOEDFrE, Unsplash license

Background

Anticancer drug sales exceeded $50 billion worldwide in 2009 with impressive growth; however, lack of target selectivity is a major challenge in cancer treatment. The limitation of current chemotherapy is in delivering high enough concentrations of cytotoxic drug to the target site in order to completely eradicate the tumor without harming healthy cells. Therefore, a technology that can enhance target selectivity would significantly improve clinical outcomes as well as quality of life for patients and thus have the potential to create novel drugs that can take over and dominate the market.

Technology

Researchers at Stony Brook University have developed novel methods and compositions to make anticancer prodrugs by conjugating unique dual-substrate biochemical modules to known or novel chemotherapeutic drugs. The requirement of sequential activation by two independent key enzymes acting in tumor cells makes the prodrugs highly selective, resulting in fewer side effects compared to existing anticancer drugs in clinical use. In addition, these novel prodrugs have been shown to be much more stable and resistant to non-specific activation by ubiquitous proteases in cytoplasm or plasma than existing prodrugs. Further Details: Ueki et al., 4:2735, 2013

Advantages

Better selectivity with minimal adverse effects - Reduced nonspecific activation by ubiquitous proteases in cytoplasm or plasma - Ability to ?repackage? existing generic chemotherapeutic drugs to improve selectivity

Application

Anticancer drug therapy - Prodrug formulation

Inventors

Michael Hayman, Professor, Molecular Genetics & Microbiology
Nobuhide Ueki, Research Scientist, Molecular Genetics & Microbiology

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Seeking to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Sean Boykevisch, Director, OTLIR, sean.boykevisch@stonybrook.edu, 6316326952

Patent Status

Issued patent: 9,872,919

Proof of concept data is available.

Electrochemical Synthesis of Chloro-Chitosan
A chitosan polymer that retains its natural biocompatibility making it ideal for environmental applications such as water filtration
Source: Macau Photo Agency, unsplash.com/photos/sZOWADU0jxU, Unsplash Licence

Background

Chitosan has extensively used polysaccharide derived from deacetilization of chitin, which is the second most abundant biopolymer. Presence of primary amine, primary hydroxyl as well as secondary hydroxyl groups make chitosan very amenable to further fictionalization and modification; consequently, chitosan has been modified in numerous ways which can be broadly classified in physical, chemical and enzymatic modification categories. Owing to extensive application of chitosan in the fields of biomedical, agriculture, water & waste treatment, food & beverages, cosmetics & toiletries and biopharmaceutics there is constant effort to develop new derivatives of chitosan.

Technology

This invention is an electrochemical modification of chitosan to synthesize a novel polymer. The polymer synthesized is a chloride form of chitosan, involving an electrochemical process to substitute one or both of hydroxyl group with chlorine. The new molecule is expected to retain its natural biocompatibility and has been found to retain hydrating properties. Substitution of hydroxyl by chlorine is expected to enhance metal chelation and binding properties of chitosan and thus is expected to perform better than the original molecule in applications including environmental applications, water filtration etc.

Advantages

Easy to scale up - Environmentally friendly by limiting the use of toxic oxidizing and reducing agent - Easy control over process parameters and hence chemistry - Can be deposited as thin films or patterned structures

Application

Synthesizing the polymer chloride

Inventors

Gary Halada, Professor, Materials Science and Engineering
Prashant Jha, Research Assistant, Material Sciences and Engineering

Licensing Potential

Licensing

Licensing Status

Exclusive license - all fields

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patented

Prototype is available for testing. PCT Publication No. WO 2013-116619

Digital Image Speckle Correlation (DISC) Analysis for Subcutaneous Muscle Motion and Nerve Function
A technique that uses photographic analysis to calculate the magnitude and vector of muscle contraction to determine nerve function
Source: Karelys Ruiz, https://unsplash.com/photos/PqyzuzFiQfY, Unsplash License.

Background

Digital Image Speckle Correlation (DISC) has previously been used in animal studies of skin dynamics. In addition, the technology has been applied toward characterizing the biomechanical properties of human skin and the effects of ageing, as well as the analysis of mechanical properties of metals. The proposed innovation will extend DISC to direct clinical applications.

Technology

Researchers at Stony Brook University have invented Digital Image Speckle Correlation (DISC) analysis, which is a novel, sensitive, and non-invasive technique that calculates the magnitude and vector of muscle contraction through photographic analysis. DISC can be used to test the efficiency of commercial skin repair products on people of different ages, gender, and ethnicity. It can also be used to determine the frequency and sites for Botox injections specific to each patient, as well as monitor facial neuroma and determine when surgery is needed. Additionally DISC can be used commercially to determine the effect of nerve function and monitor recovery in patients of Bell?s palsy, nerve repair.

Advantages

Highly cost-effective - Sensitive and non-invasive - Non-contact technique which detects subtle deformation of the skin - Uses vector displacement to determine the magnitude and direction of muscle contraction

Application

Test efficiency of commercial skin repair products - Determine the frequency and sites for Botox injections specific to each patient - Monitor facial neuroma and determine when surgery is needed

Inventors

Miriam Rafailovich, Professor of Material Science, Material Science & Chem. Engineering
Divya Bhatnagar, , Material Science & Engineering
Raphael Davis, Chairman, Neurosurgery
Alexander Dagum, Assoc. Professor, Surgery
Duc Bui, Associate Professor, Surgery

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook are seeking to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patent application submitted

Software is available for demonstration. Utility Patent Filed, Publication No. US 2013-0123647

Crosslinked Thermoreversible Pluronic Hydrogels for Prosthetic Disc Nucleus Replacement
An easily injectable crosslinked hyaluronic acid-gelatin hydrogel that can be used as a prosthetic replacement for a spinal disc nucleus

Source: Foxstudio, stock.adobe.com/uk/247988792, stock.adobe.com

Background

When a spinal disc becomes damaged due to trauma or disease resulting in a disc herniation, it may become necessary to replace a natural spinal disc nucleus with a prosthesis. Such prostheses should preferably mimic the shape and function of the natural nucleus. Several varieties of prostheses have been proposed for replacing the natural disc nucleus, however these prostheses may exert additional pressure on the annulus and can further cause deterioration. Several other implants can eventually decompose and become mobile. The present invention overcomes all the disadvantages of the previously used implanted materials.

Technology

Researchers at Stony Brook University have created a non-invasive technique for prosthetic spinal disc nucleus replacements. This treatment obviates the need for any surgical intervention in herniated spinal disc repair. Besides this, it can also be used to fill gaps or cavities, gaps in bones or other internal spaces in the body. This invention can be used by crosslinking HA and pluronic which makes the hydrogel non‑adhesive. For adhesive gels, gelatin and pluronic can be crosslinked and used for regenerative medicine.

Advantages

Thermoreversible - This hydrogel is easily injectable and FDA approved - Additional Hydrogel can be injected to compensate for degradation - Decaying hydrogel implant can be removed by cooling - Manipulation of size and compressibility of the implant

Application

Prosthetic spinal disk nucleus replacements.

Inventors

Miriam Rafailovich, Professor of Material Science, Material Science & Chem. Engineering
Raphael Davis, Chairman, Neurosurgery
Divya Bhatnagar, , Material Science & Engineering

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook is seeking to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Donna Tumminello, Assistant Director, Office of Technology Licensing, donna.tumminello@stonybrook.edu, 6316324163

Patent Status

Patented

Prototype is available for testing.PCT Publication No. WO 2013-006671

Enhancing Responses to Chemical Interventions by Programmed Introduction of Multiple Refractory Periods
A medical device that can deliver multiple, brief intervention doses over a 24 hour period that improves cell biologic responses.
Source: Anusorn, stock.adobe.com/uk/270607942, stock.adobe.com

Background

The ability of any exogenous intervention, be it physical or chemical in nature, to influence cell activity is markedly enhanced by incorporating a rest period between stimulation periods within any given 24 hour period. Thus, a 24 hour period does not need to transpire before the biologic responsiveness to a given stimulus is ?reset.?

Technology

Researchers at Stony Brook University created an invention which indicates that the potency of a given intervention can be improved, and the biologic response enhanced, by delivering it via multiple, brief doses over a day, rather than single doses in any given day. In the context of a medical device that delivers an electric or mechanical signal, the ability of that intervention to upregulate a cell response is improved by waiting at least 1 hour before introducing the signal again and is improved even more by waiting 3 hours. This allows for multiple periods of stimulus over a given day, and the outcome is improved as compared to a single dose given once per day.

Advantages

Builds on the responsiveness of the biologic system. - Can also be used in non-human applications, such as timing/optimizing yields in recombinant stills in bioprocessing or agriculture.

Application

Introduces rest periods between stimulation periods within a 24 hour period to increase the effectiveness of exogenous intervention.

Inventors

Clinton Rubin, Distinguished Professor, Biomedical Engineering

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. Stony Brook seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Sean Boykevisch, Director, OTLIR, sean.boykevisch@stonybrook.edu, 6316326952

Patent Status

Patented

Some in-vitro data is available. PCT Publication No. WO 2012-051495

Novel EGFR Truncations as Biomarker and Target
Three mutations that could be used as biomarkers for patient's drug responses or for tumor therapeutic targets
Source: National Cancer Institute, unsplash.com/photos/fd0b-Bl4cFc, Unsplash Licence

Background

Three new truncation mutants have been discovered in primary human tumors and cell lines. These mutants may possess oncogenic activities and render some tumors resistant to certain inhibitors. These newly discovered mutants may be used as biomarkers for predicting patients? response to specific targeting agents.

Technology

Researchers at Stony Brook University discovered three new truncation mutants of EGFR in primary human tumors and cell lines. These mutations may be used as biomarkers for predicting a patients? response to anti-EGFR drugs, molecular diagnostic for micrometastasis/minimal residual disease monitoring or become new therapeutic targets for drug and antibody development.

Advantages

New EGFR truncation mutants may be used for predicting patients? response to EGFR targeting agents. - Could become new therapeutic targets for drug and antibody development.

Application

Biomarker for predicting patients? response to anti-EGFR drugs. - Therapeutic target for drug and antibody development.

Inventors

Edward Chan, Assistant Professor, Pediatrics
James Keller, Research Assistant, Molecular Genetics and Microbiology

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. The team seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Sean Boykevisch, Director, OTLIR, sean.boykevisch@stonybrook.edu, 6316326952

Patent Status

Patented

Antibody developed; need clinical validation. PCT Publication No. WO 2011-140391

Methods of Treating and Preventing Angioedema and Vascular Leakage
Peptides and antibodies that block vascular permeability induced in angioedema patients that are new targets for treatment.
Please note, header image is purely illustrative. Source: ustas, stock.adobe.com/uk/212148709, stock.adobe.com

Background

Angioedema associated with C1-INH deficiency is an inherited or acquired condition that affects 20 per cent of the population. The condition can be disfiguring, painful and sometimes fatal. Existing treatments primarily replace or enhance the production of C1-INH, but these options are limited to availability, price, side effects, and long term risks. New therapeutic modalities that address these issues are sorely needed.

Technology

Researchers at Stony Brook University have identified proprietary peptides and antibodies that are being used in a novel mechanism of action to block the vascular permeability that is induced by the attack phase of plasma in the C1-INH deficient AE patients. This mechanism of action relates to blocking bradykinin (BK) production and the complement activation, key mediators of episodic AE.

Advantages

New target and compositions for the treatment of AE - Novel mechanism of action for blocking the production of BK and the complement activation

Application

Diagnostic and therapeutic applications for hereditary and drug-induced AE.

Inventors

Berhane Ghebrehiwet, DVM, DSc, Medicine and Pathology

Licensing Potential

Development partner - Commercial partner - Licensing

Licensing Status

Available for license. The team seeks to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Licensing Contact

Sean Boykevisch, Director, OTLIR, sean.boykevisch@stonybrook.edu, 6316326952

Patent Status

Patented

In vitro data is available. Issued patent # 8,883,153

Monoclonal Antibody, Anti Ft LVS LpnA/Tu14 Clone 164
An intracellular bacterium that can initiate the human response to Tularemia
Source: Gavin Allanwood, unsplash.com/photos/hcxqLJjI99E, Unsplash Licence

Background

Francisella tularensis is an intracellular, gram-negative bacterium that invades macrophages and initiates the human immune response.

Technology

Tularemia, commonly known as ?rabbit fever? can be communicated across several species including; rabbits, rodents and humans. The murine monoclonal antibody recognizes a native epitope of Francisella tularensis ?Live Vaccine Strain?; IgG monoclonal antibody clone 164 against a native epitope of Francisella tularensis protein, LpnA/Tu14.

Advantages

The antibody was developed from a mouse infected with F.tularensis live vaccine strain and not recombinant protein, therefore representing a natural antibody made by the mouse in defence of infection against the native F. tularensis protein.

Application

Western blot - ELISA - Immunoprecipitation - Immunofluorescence assays

Inventors

Jorge Benach, Professor, Molecular Genetics & Microbiology
Anne Savitt, Research Assistant Professor, Molecular Genetics & Microbiology

Licensing Potential

Licensing

Licensing Status

Available for license.

Licensing Contact

Valery Matthys, Licensing Associate, Technology Licensing, valery.matthys@stonybrook.edu,

Patent Status